EMA (EU)
EVENT
Good manufacturing practice: Multistakeholder workshop on expert contributions to artificial intelligence guidance development (Annex 22)
Published: 6/30/2026Detected: 6/20/2026
Summary preview
Plans a two-day EMA workshop to shape a risk-based approach for the use of generative AI in medicines manufacturing, focusing on how expert contributions should inform future GMP-oriented AI expectations.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026